Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

180 LIFE SCIENCES CORP.

(ATNF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

180 Life Sciences : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trials

09/20/2021 | 11:36am EST


ę MT Newswires 2021
All news about 180 LIFE SCIENCES CORP.
12/06180 Life Sciences' Clinical Study For Dupuytren's Disease Meets Primary, Secondary Endp..
MT
12/06180 LIFE SCIENCES : Life Sciences Provides Follow-Up Information on Oxford University and ..
PU
12/06180 LIFE SCIENCES CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
12/06180 Life Sciences Provides Follow-Up Information on Oxford University and the Company's..
AQ
12/06180 Life Sciences Provides Follow-Up Information on Oxford University and the Company&#..
CI
12/01180 LIFE SCIENCES : Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynot..
PU
12/01180 LIFE SCIENCES CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
12/01180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at ..
AQ
11/22180 Life Sciences Expands Patent Portfolio With Treatments Related to Chronic Pain
MT
11/22180 Life Sciences Corp. Expands Patent Portfolio
AQ
More news
Analyst Recommendations on 180 LIFE SCIENCES CORP.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -25,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,88x
Yield 2021 -
Capitalization 146 M 146 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees -
Free-Float 67,2%
Chart 180 LIFE SCIENCES CORP.
Duration : Period :
180 Life Sciences Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 180 LIFE SCIENCES CORP.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 3,95 $
Average target price 11,00 $
Spread / Average Target 178%
EPS Revisions
Managers and Directors
Jim N. Woody Chief Executive Officer & Director
Ozan Pamir Chief Financial Officer & Secretary
Lawrence J. Steinman Executive Co-Chairman
Marc Feldmann Executive Co-Chairman
Jonathan B. Rothbard Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
180 LIFE SCIENCES CORP.44.69%146
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531